A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: Results of a prospective audit and retrospective survey of patient experiences

European Journal of Oncology Nursing

Volumn 11, Issue 3, 2007, Pages 247-254

  MacLeod, A ^a   Branch, A ^a   Cassidy, J ^a   McDonald, A ^a   Mohammed, N ^a   MacDonald, L ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Audit; Capecitabine; Colorectal cancer; Nurse Pharmacy led clinic; Patient satisfaction; Patient survey

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

AGED; ARTICLE; CANCER CENTER; COLORECTAL TUMOR; DRUG MONITORING; EVALUATION; FEMALE; HEALTH CARE QUALITY; HOME CARE; HOSPITAL PHARMACY; HUMAN; LEADERSHIP; MALE; MIDDLE AGED; NURSE ATTITUDE; NURSING; NURSING EVALUATION RESEARCH; ORAL DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; OUTPATIENT DEPARTMENT; PATIENT SATISFACTION; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RETROSPECTIVE STUDY; UNITED KINGDOM;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CANCER CARE FACILITIES; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG MONITORING; FEMALE; FLUOROURACIL; HOME CARE SERVICES, HOSPITAL-BASED; HUMANS; LEADERSHIP; MALE; MIDDLE AGED; NURSE'S ROLE; NURSING AUDIT; NURSING EVALUATION RESEARCH; OUTPATIENT CLINICS, HOSPITAL; PATIENT SATISFACTION; PHARMACY SERVICE, HOSPITAL; PROGRAM EVALUATION; PROSPECTIVE STUDIES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SCOTLAND;

EID: 34447101692     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2006.10.001     Document Type: Article

References (18)

1. Birner A. Pharmacology of oral chemotherapy agents. Clinical Journal of Oncology Nursing 7 6 Suppl. (2003) 11-19
2. Cassidy J., Twelves C., van Cutsem E., Hoff P., Bajetta E., Boyer M., Bugat R., Burger U., Garin A., Graeven U., McKendric J., Maroun J., Marshall J., Osterwalder B., Perez-Manga G., Rosso R., Rougier P., Schilsky R.L., and Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 13 4 (2002) 566-575
3. Cassileth B.R., Zupkis R.V., Sutton-Smith K., and March V. Information and participation preferences among cancer patients. Annals of Internal Medicine 92 6 (1980) 832-836
4. Chau I., Legge S., and Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). European Journal of Oncology Nursing 8 Suppl. 1 (2004) S41-S53
5. Corner J. The role of nurse-led care in cancer management. Lancet Oncology 4 10 (2003) 631-636
6. Cortis J.D., and Lacey A.E. Measuring the quality and quantity of information-giving to in-patients. Journal of Advanced Nursing 24 4 (1996) 674-681
7. Department of Health (DoH). The NHS Cancer Plan (2000), HMSO, London
8. Faithfull S., and Deery P. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. European Journal of Oncology Nursing 8 Suppl. 1 (2004) S54-S62
9. Faithfull S., Corner J., Meyer L., Huddart R., and Dearnaley D. Evaluation of nurse-led follow up for patients undergoing pelvic radiotherapy. British Journal of Cancer 85 12 (2001) 1853-1864
10. Garvican L., Grimsey E., Littlejohns P., Lowndes S., and Sacks N. Satisfaction with clinical nurse specialists in a breast cancer clinic: questionnaire survey. British Medical Journal 316 7136 (1998) 976-977
11. Gerbrecht B.M., and Kangas T. Implications of capecitabine (Xeloda) for cancer nursing practice. European Journal of Oncology Nursing 8 Suppl. 1 (2004) S63-S71
12. Mills M.E., and Sullivan K. Patients with operable oesophageal cancer: their experience of information giving in a regional thoracic unit. Journal of Clinical Nursing 9 2 (2000) 236-246
13. Moore S., Corner J., Haviland J., Wells M., Salmon E., Normand C., Brada M., O'Brien M., and Smith I. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. British Medical Journal 325 7373 (2002) 1145-1151
14. O'Neill V.J., and Twelves C.J. Oral cancer treatment: developments in chemotherapy and beyond. British Journal of Cancer 87 9 (2002) 933-937
15. Sainio C., and Eriksson E. Keeping cancer patients informed: a challenge for nursing. European Journal of Oncology Nursing 7 1 (2003) 39-49
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., and Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 92 3 (2000) 205-216
17. ® Colorectal Cancer Study Group. Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer 37 5 (2001) 597-604
18. Van Cutsem E., Hoff P.M., Harper P., Bukowski R.M., Cunningham D., Dufour P., Graeven U., Lokich J., Madajewicz S., Maroun J.A., Marshall J.L., Mitchell J.L., Perez-Manga G., Rougier P., Schmiegel W., Schoelmerich J., Sobrero A., and Schilsky R.L. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. British Journal of Cancer 90 6 (2004) 1190-1197